☆ 4.8 Editorial Material

CLINICAL ONCOLOGY Windows open for cancer immunotherapy

NATURE (2018)

期刊

NATURE

卷 558, 期 7710, 页码 376-377

出版社

NATURE PUBLISHING GROUP

DOI: 10.1038/d41586-018-05312-9

关键词

-

类别

Multidisciplinary Sciences

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Oncology

Cancer-associated inflammation: pathophysiology and clinical significance

Piotr Peczek, Monika Gajda, Kacper Rutkowski, Marta Fudalej, Andrzej Deptala, Anna M. Badowska-Kozakiewicz

Summary: Cancer cells can escape immune destruction and exploit tumor-associated inflammation, leading to tumor progression. Understanding the roles of immune cell populations and reshaping tumor-associated inflammation can improve cancer therapy efficacy. Increased tumor-associated inflammation can overcome cancer-derived immunosuppression, while specific methods like cancer vaccines and chimeric antigen receptor T cells can enhance the immune system's ability to destroy cancer cells.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Review Immunology

Using the canine microbiome to bridge translation of cancer immunotherapy from pre-clinical murine models to human clinical trials

Kara T. T. Kleber, Khurshid R. R. Iranpur, Lauren M. M. Perry, Sylvia M. M. Cruz, Aryana M. M. Razmara, William T. N. Culp, Michael S. S. Kent, Jonathan A. A. Eisen, Robert B. B. Rebhun, Robert J. J. Canter

Summary: The microbiome plays an important role in tumor immunology and immunotherapy, including immune surveillance and response to immune checkpoint inhibitors. Studies using fecal microbial transplantation have shown that modulation of the gut microbiome can affect response to checkpoint immunotherapies. Canine cancer models, which closely resemble human cancers, provide valuable insights for studying microbiota-host immune and metabolic interactions and testing interventions for modifying gut microbiomes.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Immunology

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential

Espen Basmo Ellingsen, Sara M. Mangsbo, Eivind Hovig, Gustav Gaudernack

Summary: Telomerase-based therapeutic cancer vaccines have shown potential in clinical research and may enhance the efficacy of checkpoint inhibition. With its almost universal presence in cancer and essential role in tumor growth, telomerase is an attractive therapeutic target. Rational treatment combinations, such as checkpoint inhibitors, are likely necessary to fully unlock the clinical potential of telomerase-based cancer vaccines.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Oncology

New molecular and immunologic targets of therapy for esophageal cancer and the prospects for ongoing and future clinical trials

Andrew P. P. Dhanasopon

Summary: Esophageal cancer is a fatal disease globally, and advancements in various treatments have improved patients' survival rates. Targeted therapy and immunotherapy have shown efficacy for both advanced and locoregional disease, and this review discusses their molecular and immunologic targets, as well as ongoing and future clinical trials.

JOURNAL OF SURGICAL ONCOLOGY (2023)

添加到收藏夹

Review Oncology

The Immunotherapy Landscape in Adrenocortical Cancer

Guillaume J. Pegna, Nitin Roper, Rosandra N. Kaplan, Emily Bergsland, Katja Kiseljak-Vassiliades, Mouhammed Amir Habra, Yves Pommier, Jaydira Del Rivero

Summary: Adrenocortical carcinoma is a rare and life-threatening cancer that usually requires aggressive surgical interventions at early stages for a chance of cure. Treatments for advanced or metastatic disease are limited, leading to the need for research into new treatments like immunotherapies. Clinical trials testing these novel therapies for rare cancers like adrenocortical carcinoma have shown some clinical activity and are ongoing to explore potential combinations with other immune-acting agents or targeted therapies.

CANCERS (2021)

添加到收藏夹

Article Oncology

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

Tina Kringelbach, Martin Hojgaard, Kristoffer Rohrberg, Iben Spanggaard, Britt Elmedal Laursen, Morten Ladekarl, Charlotte Aaquist Haslund, Laurine Harslof, Laila Belcaid, Julie Gehl, Lise Sondergaard, Rikke Lovendahl Eefsen, Karin Holmskov Hansen, Annette Raskov Kodahl, Lars Henrik Jensen, Marianne Ingerslev Holt, Trine Heide Oellegaard, Christina Westmose Yde, Lise Barlebo Ahlborn, Ulrik Lassen

Summary: The ProTarget trial aims to investigate the anti-tumor activity and toxicity of commercially available targeted therapies in cancer patients with specific actionable genomic alterations. This national trial will provide new data and insights into molecular pathways and potentially expand personalized cancer treatment strategies.

BMC CANCER (2023)

添加到收藏夹

Article Oncology

Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge

Myung S. Kim, Vinay Prasad

Summary: The design of clinical trials with outcomes reported in cohorts including nested subgroups is common in novel agents seeking new indications for approval. This structure represents a tension between drug companies and patients, requiring a granular approach to explore optimal treatments for individual patients with different levels of PD-L1 expression.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors

Chen Wei, Mengyu Wang, Quanli Gao, Shasha Yuan, Wenying Deng, Liangyu Bie, Yijie Ma, Chi Zhang, Shuyi Li, Suxia Luo, Ning Li

Summary: A machine learning algorithm was used to develop a peripheral blood immune cell-based signature that accurately predicts the overall survival benefit of patients receiving immune checkpoint inhibitor therapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

添加到收藏夹

Article Oncology

Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer

William Butler, Lingfan Xu, Yinglu Zhou, Qing Cheng, J. Spencer Hauck, Yiping He, Robert Marek, Zachary Hartman, Liang Cheng, Qing Yang, Mu-En Wang, Ming Chen, Hong Zhang, Andrew J. Armstrong, Jiaoti Huang

Summary: Neuroendocrine (NE) cells represent a small percentage of epithelial cells in the prostate, but they become more abundant in hormonally treated and castration-resistant prostate cancer (CRPC). In some cases, hormonally treated tumors can recur as small cell NE carcinoma (SCNC), which are composed entirely of NE cells. NE cells are resistant to hormonal therapy due to their lack of androgen receptors (ARs). A study has found that glypican-3 (GPC3) is specifically expressed by NE cells in prostate cancer and plays a critical role in their viability and differentiation.

JOURNAL OF PATHOLOGY (2023)

添加到收藏夹

Review Oncology

Minimally Invasive and Open Gastrectomy for Gastric Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials

Matthew G. G. Davey, Hugo C. C. Temperley, Niall J. J. O'Sullivan, Vianka Marcelino, Odhran K. Ryan, Eanna J. Ryan, Noel E. E. Donlon, Sean M. M. Johnston, William B. B. Robb

Summary: This study aimed to compare the outcomes of open gastrectomy, laparoscopic-assisted gastrectomy, and robotic gastrectomy for gastric cancer through a network meta-analysis. The results showed that laparoscopic-assisted gastrectomy and robotic gastrectomy were not inferior to open gastrectomy in terms of oncological and surgical outcomes. Additionally, laparoscopic-assisted gastrectomy had fewer surgical traumas and shorter recovery time.

ANNALS OF SURGICAL ONCOLOGY (2023)

添加到收藏夹

Article Medicine, Research & Experimental

RAD21 Amplification Epigenetically Suppresses Interferon Signaling to Promote Immune Evasion in Ovarian Cancer

Peng Deng, Zining Wang, Jinghong Chen, Shini Liu, Xiaosai Yao, Shaoyan Liu, Lizhen Liu, Zhaoliang Yu, Yulin Huang, Zhongtang Xiong, Rong Xiao, Jiuping Gao, Weiting Liang, Jieping Chen, Hui Liu, Jinghan Hong, Jason Yongsheng Chan, Peiyong Guan, Jianfeng Chen, Yali Wang, Jiaxin Yin, Jundong Li, Min Zheng, Chao Zhang, Penghui Zhou, Tiebang Kang, Bin Tean Teh, Qiang Yu, Zhixiang Zuo, Qingping Jiang, Jihong Liu, Ying Xiong, Xiaojun Xia, Jing Tan

Summary: In this study, RAD21 overexpression in ovarian cancer was found to be inversely correlated with IFN signature gene expression. RAD21 was shown to directly interact with YAP/TEAD4 and recruit NuRD complex to suppress IFN signaling. The study also demonstrated that RAD21 ablation enhanced the efficacy of anti-PD-1 treatment, suggesting RAD21 as a potential target and biomarker for precision immunotherapy in ovarian cancer.

JOURNAL OF CLINICAL INVESTIGATION (2022)

添加到收藏夹

Review Oncology

Precision medicine for metastatic colorectal cancer in clinical practice

Julian E. Riedesser, Matthias P. Ebert, Johannes Betge

Summary: This review summarizes recent advances in personalized treatment for patients with metastatic colorectal cancer. We provide an overview of current multimodal therapy and explain novel immunotherapy and targeted therapy approaches in detail. We emphasize clinically relevant therapies and provide recommendations for clinical practice.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Analysis of the Equilibrium Phase in Immune-Controlled Tumors Provides Hints for Designing Better Strategies for Cancer Treatment

Kevin Atsou, Sokchea Khou, Fabienne Anjuere, Veronique M. Braud, Thierry Goudon

Summary: This study reveals the key biological parameters that influence the equilibrium state of cancer and proposes strategies to maintain tumor equilibrium based on numerical models and computational methods, providing clues for the design and optimization of cancer treatments.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Immunology

Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs

Rachel V. Brady, Douglas H. Thamm

Summary: Macrophages, ancient immune cells, play diverse roles in development, homeostasis, tissue repair, inflammation, and immunity. In cancer, most tumor-associated immune cells are macrophages, with both anti-tumor and pro-tumorigenic properties. Manipulating macrophages as a therapeutic strategy against cancer has been of interest since the 1970s. Companion dogs serve as a valuable comparative immuno-oncology model, and data from clinical trials in humans and dogs can contribute to scientific advancements for both species. This review provides an overview of macrophages in general and focuses on their role as a therapeutic strategy against cancer in humans and companion dogs.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Review Oncology

Targeting breast cancer stem cells directly to treat refractory breast cancer

Liping Pan, Juan Han, Ming Lin

Summary: For patients with refractory breast cancer, integrative immunotherapies are becoming crucial in treatment. However, many patients do not respond to treatment or relapse. The tumor microenvironment and cancer stem cells play important roles in the progression of breast cancer. Modulating the immune system and targeting breast cancer stem cells directly are essential strategies for improving therapeutic efficacy.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

Roberto Ferrara, Marie Naigeon, Edouard Auclin, Boris Duchemann, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Laura Mezquita, Matthieu Texier, Caroline Caramella, Lizza Hendriks, David Planchard, Jordi Remon, Sabina Sangaletti, Claudia Proto, Marina C. Garassino, Jean-Charles Soria, Aurelien Marabelle, Anne-Laure Voisin, Siham Farhane, Benjamin Besse, Nathalie Chaput

Summary: T-cell immunosenescence is observed in up to 28% of patients with aNSCLC, correlating with lack of benefit from ICI treatment but not from PCT.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares

Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy

Ithar Gataa, Laura Mezquita, Caroline Rossoni, Edouard Auclin, Myriam Kossai, Frank Aboubakar, Sylvestre Le Moulec, Julie Masse, Morgane Masson, Nina Radosevic-Robin, Pierre Alemany, Mathieu Rouanne, Virginia Bluthgen, Lizza Hendriks, Caroline Caramella, Anas Gazzah, David Planchard, Jean-Pierre Pignon, Benjamin Besse, Julien Adam

Summary: High-TIL was associated with favorable outcomes in a real-world immunotherapy cohort of patients with NSCLC, but not with chemotherapy, suggesting that TILs may be useful in selecting patients for immunotherapy.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Editorial Material Oncology

Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC

Jordi Remon, Lizza E. L. Hendriks

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Review Cell Biology

Biomarkers of Radiotherapy-Induced Immunogenic Cell Death

Rianne D. W. Vaes, Lizza E. L. Hendriks, Marc Vooijs, Dirk De Ruysscher

Summary: Radiation therapy can induce immunogenic cell death and release various immunogenic factors, but the search for biomarkers predicting immunogenic cell death in tumor cells remains limited. This review summarizes the available literature on potential biomarkers of radiation-induced immunogenic cell death evaluated in cancer patients and discusses their clinical relevance.

CELLS (2021)

添加到收藏夹

Article Oncology

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Laura Mezquita, Isabel Preeshagul, Edouard Auclin, Diana Saravia, Lizza Hendriks, Hira Rizvi, Wungki Park, Ernest Nadal, Patricia Martin-Romano, Jose C. Ruffinelli, Santiago Ponce, Clarisse Audigier-Valette, Simona Carnio, Felix Blanc-Durand, Paolo Bironzo, Fabrizio Tabbo, Maria Lucia Reale, Silvia Novello, Matthew D. Hellmann, Peter Sawan, Jeffrey Girshman, Andrew J. Plodkowski, Gerard Zalcman, Margarita Majem, Melinda Charrier, Marie Naigeon, Caroline Rossoni, AnnaPaola Mariniello, Luis Paz-Ares, Anne Marie Dingemans, David Planchard, Nathalie Cozic, Lydie Cassard, Gilberto Lopes, Nathalie Chaput, Kathryn Arbour, Benjamin Besse

Summary: In patients with aNSCLC receiving ICI treatment, high dNLR at baseline (B) correlated with worse PFS/OS, while high dNLR at cycle 2 (C2) was associated with even poorer outcomes. Persistently high dNLR (B+C2) was linked to early ICI failure, suggesting immature neutrophils may play a key role in ICI resistance.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Editorial Material Oncology

Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer

Jordi Remon, Lizza E. L. Hendriks, Benjamin Besse

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma-A Systematic Review

Anita Brouns, Safiye Dursun, Gerben Bootsma, Anne-Marie C. Dingemans, Lizza Hendriks

Summary: Around 30-60% of lung cancer patients develop bone metastases, with those carrying an EGFR mutation being more prone to it. However, there is still a lack of research on bone metastases in clinical trials.

CANCERS (2021)

添加到收藏夹

Article Oncology

Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials

Julie Delorme, Valentin Charvet, Muriel Wartelle, Francois Lion, Bruno Thuillier, Sandrine Mercier, Jean-Charles Soria, Mikael Azoulay, Benjamin Besse, Christophe Massard, Antoine Hollebecque, Loic Verlingue

Summary: The study aimed to predict successful completion of screening and dose-limiting toxicity period in early-phase oncology trials using machine learning. By transforming consultation reports into semantic vectors and clustering them, a model was trained to achieve high performance in predicting patient outcomes.

JCO CLINICAL CANCER INFORMATICS (2021)

添加到收藏夹

Article Oncology

Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study

Rianne D. W. Vaes, Kobe Reynders, Jenny Sprooten, Kathleen T. Nevola, Kasper M. A. Rouschop, Marc Vooijs, Abhishek D. Garg, Maarten Lambrecht, Lizza E. L. Hendriks, Marijana Rucevic, Dirk De Ruysscher

Summary: The study aimed to identify immunogenic proteins correlated with progression-free survival in NSCLC patients, providing a starting point for future immune profiling analyses in clinical trials.

CANCERS (2021)

添加到收藏夹

Article Oncology

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

Alexander Drilon, Joshua C. Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M. Gadgeel, D. Ross Camidge, Anthonie J. van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S. Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R. Soglia, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola Zhu, Monika A. Davare, Aaron N. Hata, Henry E. Pelish, Jessica J. Lin

CANCER DISCOVERY (2023)

添加到收藏夹

Article Oncology

The Association of Gross Tumor Volume and Its Radiomics Features with Brain Metastases Development in Patients with Radically Treated Stage III Non-Small Cell Lung Cancer

Haiyan Zeng, Fariba Tohidinezhad, Dirk K. M. De Ruysscher, Yves C. P. Willems, Juliette H. R. J. Degens, Vivian E. M. van van den Boogaart, Cordula Pitz, Francesco Cortiula, Lloyd Brandts, Lizza E. L. Hendriks, Alberto Traverso

Summary: Clinical risk factors, including age, NSCLC subtype, and GTVn, were identified as significant predictors for brain metastases (BM) development. Radiomics features measuring tumor heterogeneity were found to be the most relevant. The GTVn radiomics model showed the best performance in predicting BM.

CANCERS (2023)

添加到收藏夹

Editorial Material Oncology

Does perioperative immunotherapy reduce the risk of second primary cancers?

Marco Tagliamento, Jordi Remon, David Planchard, Benjamin Besse

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A-M C. Dingemans, M. Fruh, A. Ardizzoni, B. Besse, C. Faivre-Finn, L. E. Hendriks, S. Lantuejoul, S. Peters, N. Reguart, C. M. Rudin, D. De Ruysscher, P. E. Van Schil, J. Vansteenkiste, M. Reck

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations

Bart Koopman, Harry J. M. Groen, Marjolijn J. L. Ligtenberg, Katrien Grunberg, Kim Monkhorst, Adrianus J. de Langen, Mirjam C. Boelens, Marthe S. Paats, Jan H. von der Thusen, Winand N. M. Dinjens, Nienke Solleveld, Tom van Wezel, Hans Gelderblom, Lizza E. Hendriks, Ernst-Jan M. Speel, Tom E. Theunissen, Leonie I. Kroeze, Niven Mehra, Berber Piet, Anthonie J. van der Wekken, Arja ter Elst, Wim Timens, Stefan M. Willems, Ruud W. J. Meijers, Wendy W. J. de Leng, Anne S. R. van Lindert, Teodora Radonic, Sayed M. S. Hashemi, Danielle A. M. Heideman, Ed Schuuring, Leon C. van Kempen

Summary: This study evaluates the methods and agreement in treatment recommendations among Molecular Tumor Boards (MTBs) from tertiary cancer referral centers in The Netherlands. It found that these MTBs are similar in setup and demonstrate high agreement in recommendations for rare or complex mutational cancer profiles. The proposed Dutch MTB model focuses on collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.

ONCOLOGIST (2021)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.